Insulin Induces Swelling-dependent Activation of the Epidermal Growth Factor Receptor in Rat Liver
Overview
Affiliations
The aim of the study was to analyze whether the proliferative effects of insulin in rat liver involve cross-signaling toward the epidermal growth factor receptor (EGFR) and whether this is mediated by insulin-induced hepatocyte swelling. Studies were performed in the perfused rat liver and in primary rat hepatocytes. Insulin (35 nmol/liter) induced phosphorylation of the EGFR at position Tyr(845) and Tyr(1173), but not at Tyr(1045), suggesting that EGF is not involved in insulin-induced EGFR activation. Insulin-induced EGFR phosphorylation and subsequent ERK1/2 phosphorylation were sensitive to bumetanide, indicating an involvement of insulin-induced hepatocyte swelling. In line with this, hypoosmotic (225 mosmol/liter) hepatocyte swelling also induced EGFR and ERK1/2 activation. Insulin- and hypoosmolarity-induced EGFR activation were sensitive to inhibition by an integrin-antagonistic RGD peptide, an integrin beta1 subtype-blocking antibody, and the c-Src inhibitor PP-2, indicating the involvement of the recently described integrin-dependent osmosensing/signaling pathway (Schliess, F., Reissmann, R., Reinehr, R., vom Dahl, S., and Häussinger, D. (2004) J. Biol. Chem. 279, 21294-21301). As shown by immunoprecipitation studies, insulin and hypoosmolarity induced a rapid, RGD peptide-, integrin beta1-blocking antibody and PP-2-sensitive association of c-Src with the EGFR. As for control, insulin-induced insulin receptor substrate-1 phosphorylation remained unaffected by the RGD peptide, PP-2, or inhibition of the EGFR tyrosine kinase activity by AG1478. Both insulin and hypoosmolarity induced a significant increase in BrdU uptake in primary rat hepatocytes, which was sensitive to RGD peptide-, integrin beta1-blocking antibody, PP-2, AG1478, and PD098059. It is concluded that insulin- or hypoosmolarity-induced hepatocyte swelling triggers an integrin- and c-Src kinase-dependent EGFR activation, which may explain the proliferative effects of insulin.
Urushihara Y, Hashimoto T, Fujishima Y, Hosoi Y Int J Mol Sci. 2023; 24(16).
PMID: 37629008 PMC: 10454868. DOI: 10.3390/ijms241612828.
Hou J, Ma R, Zhu S, Wang Y Int J Mol Sci. 2022; 23(17).
PMID: 36077440 PMC: 9455996. DOI: 10.3390/ijms231710045.
Swelling-induced upregulation of miR-141-3p inhibits hepatocyte proliferation.
Bardeck N, Paluschinski M, Castoldi M, Kordes C, Gorg B, Stindt J JHEP Rep. 2022; 4(4):100440.
PMID: 35287291 PMC: 8917307. DOI: 10.1016/j.jhepr.2022.100440.
c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?.
Belli S, Esposito D, Servetto A, Pesapane A, Formisano L, Bianco R Cancers (Basel). 2020; 12(6).
PMID: 32517369 PMC: 7352780. DOI: 10.3390/cancers12061489.
Rohn F, Kordes C, Buschmann T, Reichert D, Wammers M, Poschmann G Aging Cell. 2020; 19(4):e13131.
PMID: 32157808 PMC: 7189994. DOI: 10.1111/acel.13131.